The Food and Drug Administration is seeking a permanent injunction against the marketing of unapproved new drugs by three corporations and one individual. The products, laetrile, in injectable and tablet form, and apricot seeds, are promoted and sold as cancer treatments by two Florida corporations and one Arizona business.
To help you add to your information arsenal on laetrile, this Vidyya issue contains a complementary and
alternative medicine (CAM) information overview on the use of laetrile as an anticancer treatment. The summary includes a history of laetrile research, a review of laboratory studies, the results of clinical trials, and possible side effects of laetrile use.
In other cancer-related news, the National Cancer Institute (NCI) is recruiting 3,000 current and former smokers for the Lung Screening Study, a year-long, $3 million study of spiral computed tomography (CT) scans, promising but unproven technology for lung cancer screening. While the study will not determine if the scans save lives – the gold standard for any cancer screening test – it will gauge the feasibility of a larger, longer study designed for that goal.
In research news, OmniComm Systems, Inc. announced it is partnering with Optima Worldwide, Ltd., to launch US testing of a new vaginal gel for the potential prevention of pregnancy and the most common sexually transmitted diseases.
And finally, a study released yesterday by the New England Journal Of Medicine is being repeated in several publications and broadcast by nearly every major media outlet. As a result, female patients who may be experiencing a downturn in their libidos may inquire about the subject of the study--the testosterone patch. Read a short study of the summary in today's Vidyya.
The articles in today's Vidyya are:
As always, we hope you enjoy the issue.